Germany’s Bayer (NYSE: ETR) has announced the extension of its 2013 collaboration agreement with the US-based research center, the Broad Institute, until 2028. The partnership focuses on identifying new drug targets in oncology and developing innovative cancer therapies. The financial details of the extended agreement have not been disclosed.
Combining Expertise for Clinical Advancements
The synergy between the Broad Institute’s expertise in cancer biology and drug discovery, and Bayer’s strengths in drug development, has proven fruitful thus far. Their collaborative efforts have yielded three clinical candidates. One of these is a mutant EGFR/HER2 inhibitor, which is currently in a Phase I study, showcasing the progress made in translating research into potential therapeutic solutions.-Fineline Info & Tech
